SG165419A1 - 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1- propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5 amine - Google Patents

7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1- propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5 amine

Info

Publication number: SG165419A1
Authority: SG; Singapore
Prior art keywords: benzisoxazol; triazolo; pyrazolo; pyrimidin; propynyl
Prior art date: 2005-09-23

Application number

SG201006970-6A

Other languages

English (en)

Inventor

Craig D Boyle

Samuel Chackalamannil

Unmesh G Shah

Jean E Lachowicz

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-23

Filing date

2006-09-21

Publication date

2010-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37487759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG165419(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-21 Application filed by Schering Corp filed Critical Schering Corp

2010-10-28 Publication of SG165419A1 publication Critical patent/SG165419A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG201006970-6A 2005-09-23 2006-09-21 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1- propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5 amine SG165419A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US72002705P	2005-09-23	2005-09-23

Publications (1)

Publication Number	Publication Date
SG165419A1 true SG165419A1 (en)	2010-10-28

Family

ID=37487759

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG201006970-6A SG165419A1 (en)	2005-09-23	2006-09-21	7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1- propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5 amine

Country Status (30)

Country	Link
US (2)	US7572802B2 (es)
EP (1)	EP1937687B1 (es)
JP (1)	JP4808779B2 (es)
KR (1)	KR101396614B1 (es)
CN (2)	CN102716131B (es)
AR (1)	AR056080A1 (es)
AT (1)	ATE503759T1 (es)
AU (1)	AU2006294633B8 (es)
BR (1)	BRPI0616264B8 (es)
CA (1)	CA2623047C (es)
CY (1)	CY1111921T1 (es)
DE (1)	DE602006021042D1 (es)
DK (1)	DK1937687T3 (es)
EC (1)	ECSP088297A (es)
ES (1)	ES2361856T3 (es)
HR (1)	HRP20110466T1 (es)
IL (1)	IL190275A (es)
MY (1)	MY146429A (es)
NO (1)	NO341760B1 (es)
NZ (1)	NZ566737A (es)
PE (1)	PE20070521A1 (es)
PL (1)	PL1937687T3 (es)
PT (1)	PT1937687E (es)
RS (1)	RS51702B (es)
RU (1)	RU2417997C2 (es)
SG (1)	SG165419A1 (es)
SI (1)	SI1937687T1 (es)
TW (1)	TWI335329B (es)
WO (1)	WO2007038284A1 (es)
ZA (1)	ZA200802550B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ527142A (en)	2003-07-23	2006-03-31	Douglas Pharmaceuticals Ltd	A stable suspension formulation
US7691869B2 (en)	2007-03-30	2010-04-06	King Pharmaceuticals Research And Development, Inc.	Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
WO2010103547A2 (en)	2009-03-13	2010-09-16	Advinus Therapeutics Private Limited	Substituted fused pyrimidine compounds
EP2462144B1 (en) *	2009-08-07	2017-09-20	Merck Sharp & Dohme Corp.	PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
WO2011101861A1 (en)	2010-01-29	2011-08-25	Msn Laboratories Limited	Process for preparation of dpp-iv inhibitors
CN103261202B (zh) *	2010-09-24	2016-01-20	阿迪维纳斯疗法有限公司	作为腺苷受体拮抗剂的稠合三环化合物
WO2012135083A1 (en) *	2011-03-31	2012-10-04	Merck Sharp & Dohme Corp.	METABOLITES OF 7-(2-(4-(6-FLUORO-3-METHYLBENZO[d]ISOXAZOL-5-YL)PIPERAZIN-1-YL)ETHYL)-2-(PROP-1-YNYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) *	2012-12-28	2014-07-03	Merck Sharp & Dohme Corp.	Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014101120A1 (en)	2012-12-28	2014-07-03	Merck Sharp & Dohme Corp.	Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014128882A1 (ja) *	2013-02-21	2014-08-28	医療法人和楽会	不安うつ病の治療薬
WO2015027431A1 (en)	2013-08-29	2015-03-05	Merck Sharp & Dohme Corp.	2,2-difluorodioxolo a2a receptor antagonists
CA2965741C (en) *	2014-11-03	2022-05-17	Iomet Pharma Ltd	Pharmaceutical compound
EP3227299B1 (en) *	2014-12-04	2021-05-26	Merck Sharp & Dohme Corp.	Formulation inhibiting effects of low acid environment
CN106543095B (zh) *	2016-09-23	2019-03-05	江苏大学	一种基于2-羟基苯乙酮肟及其衍生物一锅制备苯并异噁唑的方法
EP3723754A4 (en)	2017-12-13	2021-05-19	Merck Sharp & Dohme Corp.	IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
CN110742893B (zh) *	2018-07-23	2024-04-05	百济神州(北京)生物科技有限公司	A2a受体拮抗剂治疗癌症的方法
PE20211768A1 (es)	2018-11-30	2021-09-07	Merck Sharp & Dohme	Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE462170B (sv)	1987-10-27	1990-05-14	Aahlstrom Corp	Avlaegsnande av loesta och kolloidala makromolekylaera organiska aemnen ur effluenter
IT1264901B1 (it)	1993-06-29	1996-10-17	Schering Plough S P A	Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en)	1993-07-27	1995-02-09	Kyowa Hakko Kogyo Co., Ltd.	Remedy for parkinson's disease
IT1275420B (it)	1995-06-02	1997-08-05	Schering Plough S P A	Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
IT1277392B1 (it)	1995-07-28	1997-11-10	Schering Plough S P A	Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
DE19604919A1 (de) *	1996-02-01	1997-08-07	Schering Ag	Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
IT1291372B1 (it)	1997-05-21	1999-01-07	Schering Plough S P A	Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
IL152726A0 (en)	2000-05-26	2003-06-24	Schering Corp	Adenosine a2a receptor antagonists
GB0100624D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VII
AR037243A1 (es)	2001-10-15	2004-11-03	Schering Corp	Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
EP2295047A3 (en)	2002-12-19	2011-05-18	Schering Corporation	Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders
PT1622912E (pt) *	2003-04-23	2009-08-17	Schering Corp	Antagonistas 2-alcinil- e 2-alcenilpirazolo-[4,3-b]-1,2,4- triazolo-[1,5-c]-pirimidina do receptor a2a da adenosina
ATE461932T1 (de)	2004-04-21	2010-04-15	Schering Corp	Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors

2006
- 2006-09-20 AR ARP060104110A patent/AR056080A1/es active IP Right Grant
- 2006-09-20 PE PE2006001140A patent/PE20070521A1/es active IP Right Grant
- 2006-09-21 SG SG201006970-6A patent/SG165419A1/en unknown
- 2006-09-21 MY MYPI20080750A patent/MY146429A/en unknown
- 2006-09-21 US US11/525,065 patent/US7572802B2/en active Active
- 2006-09-21 CN CN201110394181.7A patent/CN102716131B/zh not_active Expired - Fee Related
- 2006-09-21 AT AT06804036T patent/ATE503759T1/de active
- 2006-09-21 TW TW095134895A patent/TWI335329B/zh not_active IP Right Cessation
- 2006-09-21 RS RS20110262A patent/RS51702B/sr unknown
- 2006-09-21 WO PCT/US2006/037003 patent/WO2007038284A1/en not_active Ceased
- 2006-09-21 PT PT06804036T patent/PT1937687E/pt unknown
- 2006-09-21 JP JP2008532422A patent/JP4808779B2/ja not_active Expired - Fee Related
- 2006-09-21 ES ES06804036T patent/ES2361856T3/es active Active
- 2006-09-21 CN CN2006800352004A patent/CN101273045B/zh not_active Expired - Fee Related
- 2006-09-21 AU AU2006294633A patent/AU2006294633B8/en not_active Ceased
- 2006-09-21 HR HR20110466T patent/HRP20110466T1/hr unknown
- 2006-09-21 NZ NZ566737A patent/NZ566737A/en not_active IP Right Cessation
- 2006-09-21 EP EP06804036A patent/EP1937687B1/en active Active
- 2006-09-21 RU RU2008115239/04A patent/RU2417997C2/ru active
- 2006-09-21 PL PL06804036T patent/PL1937687T3/pl unknown
- 2006-09-21 KR KR1020087007052A patent/KR101396614B1/ko not_active Expired - Fee Related
- 2006-09-21 CA CA2623047A patent/CA2623047C/en not_active Expired - Fee Related
- 2006-09-21 BR BRPI0616264A patent/BRPI0616264B8/pt not_active IP Right Cessation
- 2006-09-21 DK DK06804036.9T patent/DK1937687T3/da active
- 2006-09-21 DE DE602006021042T patent/DE602006021042D1/de active Active
- 2006-09-21 SI SI200631017T patent/SI1937687T1/sl unknown
2008
- 2008-03-18 IL IL190275A patent/IL190275A/en active IP Right Grant
- 2008-03-19 ZA ZA200802550A patent/ZA200802550B/xx unknown
- 2008-03-19 EC EC2008008297A patent/ECSP088297A/es unknown
- 2008-04-22 NO NO20081924A patent/NO341760B1/no not_active IP Right Cessation
2009
- 2009-07-06 US US12/498,013 patent/US8389532B2/en active Active
2011
- 2011-06-28 CY CY20111100618T patent/CY1111921T1/el unknown

Also Published As

Publication number	Publication date
AU2006294633B2 (en)	2012-03-01
RU2008115239A (ru)	2009-10-27
TWI335329B (en)	2011-01-01
CN101273045A (zh)	2008-09-24
ZA200802550B (en)	2009-06-24
EP1937687B1 (en)	2011-03-30
SI1937687T1 (sl)	2011-07-29
US20090270432A1 (en)	2009-10-29
RS51702B (sr)	2011-10-31
CA2623047C (en)	2013-04-23
CY1111921T1 (el)	2015-11-04
HRP20110466T1 (hr)	2011-08-31
PL1937687T3 (pl)	2011-09-30
CN102716131A (zh)	2012-10-10
BRPI0616264B1 (pt)	2020-12-22
JP2009509959A (ja)	2009-03-12
NO20081924L (no)	2008-05-22
ECSP088297A (es)	2008-04-28
BRPI0616264A2 (pt)	2011-06-14
DK1937687T3 (da)	2011-07-18
HK1119681A1 (en)	2009-03-13
US20070072867A1 (en)	2007-03-29
KR101396614B1 (ko)	2014-05-16
CA2623047A1 (en)	2007-04-05
AU2006294633A1 (en)	2007-04-05
MY146429A (en)	2012-08-15
EP1937687A1 (en)	2008-07-02
CN101273045B (zh)	2012-02-01
DE602006021042D1 (de)	2011-05-12
JP4808779B2 (ja)	2011-11-02
AR056080A1 (es)	2007-09-19
AU2006294633B8 (en)	2012-03-29
NZ566737A (en)	2011-09-30
NO341760B1 (no)	2018-01-15
ATE503759T1 (de)	2011-04-15
BRPI0616264B8 (pt)	2021-05-25
PE20070521A1 (es)	2007-07-13
KR20080047423A (ko)	2008-05-28
WO2007038284A1 (en)	2007-04-05
US8389532B2 (en)	2013-03-05
PT1937687E (pt)	2011-06-01
RU2417997C2 (ru)	2011-05-10
ES2361856T3 (es)	2011-06-22
AU2006294633A8 (en)	2012-03-29
CN102716131B (zh)	2014-04-23
IL190275A0 (en)	2009-09-22
TW200730531A (en)	2007-08-16
IL190275A (en)	2014-06-30
US7572802B2 (en)	2009-08-11

Publication	Publication Date	Title
IL190275A0 (en)	2009-09-22	7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5 AMINE
TWI369356B (en)	2012-08-01	Tetrahydropyridoindole derivatives
IL180481A0 (en)	2007-06-03	Aryl-pyridine derivatives
AP2006003767A0 (en)	2006-10-31	Morpholine compounds
ATE415400T1 (de)	2008-12-15	Pyrazolopyridinderivate
ZA200610102B (en)	2008-08-27	Pyrrazolo-pyrimidine derivatives
IL179603A0 (en)	2007-05-15	Pyrrolopyridine derivatives
IL182697A0 (en)	2007-09-20	Halogen substituted benzodiazepine derivatives
GB0414272D0 (en)	2004-07-28	OsK1 derivatives
ZA200608589B (en)	2007-12-27	Dosage form having polymorphic stability
IL179444A0 (en)	2007-05-15	4-phenyl-pyrimidine-2-carbonitrile derivatives
SI1740574T1 (sl)	2007-12-31	Derivati 4-amino-5-cianopirimidina
GB2433993B (en)	2010-04-28	Single molecule TR-FRET probe
PL1798356T3 (pl)	2017-10-31	Układ cokołowego końcowego profilu tynkarskiego
GB0326148D0 (en)	2003-12-17	Morpholine derivatives
GB0423007D0 (en)	2004-11-17	Foldable chair for bathroom
SG155924A1 (en)	2009-10-29	2-acylaminothiazole derivatives
ZA200609864B (en)	2008-08-27	Pyrrolopyridine derivatives
ZA200702343B (en)	2008-09-25	Aminoalcohol derivatives
GB0422398D0 (en)	2004-11-10	Pyridopyrimidine derivatives
GB0422395D0 (en)	2004-11-10	Pyrimidopyrimidine derivatives
GB0406657D0 (en)	2004-04-28	The use of non-opiates for the potentiation of opiates
HU0400338D0 (en)	2004-04-28	New substituted benzodiazepine derivatives
GB0411078D0 (en)	2004-06-23	Bicyclic derivatives
GB0405905D0 (en)	2004-04-21	Azaquinazoline derivatives